SGI-DNA Launches the BioXp™ 3200 System Early Access Program
BioXp™ System Provides Scientists with Ability to Create High Quality, Synthetic DNA Fragments; Key to Constructing Synthetic Genes, Gene Pathways and Whole Genomes
LA JOLLA, Calif., April 2, 2015 /PRNewswire/ -- SGI-DNA Inc. today announced the launch of the BioXp™ 3200 System Early Access Program giving researchers priority access to this one of a kind, personal DNA work station which delivers high quality synthetic DNA fragments. The BioXp™ Instrument has the capacity to simultaneously build 32 unique double-stranded DNA fragments. It is the first instrument system of its kind and empowers researchers with the ability to produce high quality synthetic DNA fragments virtually hands free.
Daniel Gibson, Ph.D., VP DNA Technology at Synthetic Genomics, Inc. states, "The vision is to evolve this system with greater capabilities by continuing to develop downstream applications for synthetic biology. Over time, the BioXp™ System will allow researchers to focus on experimental design instead of performing many of the tedious tasks of cloning and expression."
In addition to the opportunity to significantly advance their synthetic biology research, Early Access Program customers will enjoy exclusive perks such as an enhanced level of technical and customer support, including priority treatment of obtaining their constructs whether provided via BioXp™ DNA Assembly reagents or through SGI-DNA's custom synthesis service that excels in synthesizing long and difficult constructs.
The BioXp™ system utilizes the Gibson Assembly® technology and is coupled with a unique error correction formulation resulting in the synthesis of highly accurate DNA fragments. DNA fragments are ready for many applications including off-line sequencing, cloning, assembly into larger fragments, and expression into RNA and proteins. SGI-DNA's custom gene synthesis service option provides synthesis of longer and more challenging constructs for all gene synthesis needs for customers.
The Gibson Assembly® method was developed in 2009 by Daniel Gibson, Ph.D., and his colleagues at the J. Craig Venter Institute during the team's quest to construct the first synthetic cell. Since its introduction to the life science community, the Gibson Assembly® method has become a mainstay in many synthetic biology laboratories and has attracted interest from both the academic and commercial life sciences community due to its ease-of-use, robustness, and flexibility.
For more information on the BioXp™ 3200 System, please visit www.sgidna.com/bxp3200. You may also email your request to [email protected]. SGI-DNA is a member of the International Gene Synthesis Consortium.
All products are for research use only and are not intended for diagnostic uses.
About SGI-DNA
SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI), is responsible for all commercial aspects of SGI's synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Hamilton Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services.
SGI-DNA Contact:
Mary Canady, 858-433-4994, [email protected]
Logo - http://photos.prnewswire.com/prnh/20141120/160071LOGO
SOURCE SGI-DNA
Share this article